Big Changes for USP - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Big Changes for USP
Feedback is urged on USP's proposed revisions to the General Notices.


Pharmaceutical Technology


The General Notices Project Team requests feedback by Oct. 31, 2007. Comments should be sent to Neil Schwarzwalder,
, Lynn Best,
, or the team member representing your organization.

Neil Schwarzwalder is a global compendial consultant for Global Quality Laboratories, Eli Lilly and Company, tel. 317.276.9787 fax 317.433.0268

<WEBLINK>
For additional resources and online exclusives on this topic, visit http://pharmtech.com/.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here